E.U. Targets AstraZeneca In Crackdown On Patent Abuse

Law360, New York (June 14, 2005, 12:00 AM EDT) -- In the first European antitrust crackdown on patent abuse, the European Commission is expected to fine AstraZeneca on Wednesday for systematically exploiting patent regulations to thwart generic competition.

The European Union’s executive body has concluded that AstraZeneca violated antitrust regulations by concealing from patent offices the date at which it first received marketing authorization for the anti-ulcer drug Losec, government sources say.

The move allowed AstraZeneca to claim an extension of the period during which the drug is protected by patent, according to the Commission. The...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.